BioSpace News Archive

Scientists at Klick Applied Sciences have discovered a way to transform a continuous glucose monitor (CGM) into a powerful diabetes screening and prevention tool using artificial intelligence.

Ovid Therapeutics Inc. (NASDAQ: OVID) today announced that preclinical data supporting its OV329 and OV350 programs in epilepsy and treatment-resistant seizures will be presented at the 2022 American Epilepsy Society (AES) Annual Meeting, taking place December 2-6 in Nashville, Tennessee.

Neurelis, Inc., announced the company will present nine posters at the 76th American Epilepsy Society Annual Meeting (AES), December 2 – 6, 2022, Nashville, TN.

Natus Medical Incorporated has entered into a definitive agreement to acquire Micromed Holding SAS, a global provider of neurophysiology solutions.

Global Oncolytic Virus Immunotherapy Market and Clinical Trials Insight 2028 Report Overview:

Global Controlled Release Drug Delivery Market Opportunity, Drug Pricing & Clinical Trials Insight 2028 Report Overview:

Rejoni, a privately held medical technology company designing and developing hydrogels to improve the standard of care in Women’s Health, announced today that it has begun enrollment of patients in the Juveena Hydrogel System Pivotal Study.

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced new data from the OPTIMA II study designed to obtain long-term follow-up data on UGN-102 that shows median duration of response (DOR) of 24.4 months for UroGen’s investigational drug UGN-102 currently in Phase 3 development for low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).

The global small molecule innovator CDMO market size was valued at USD 41.1 billion in 2020, and is predicted to be worth around USD 73.9 billion by 2030, registering a CAGR of 6.4% during the forecast period 2022 to 2030.

According to Research Report Study, the global omics-based clinical trials market size was valued at USD 25.2 billion in 2020, and is predicted to be worth around USD 50.5 billion by 2030, registering a CAGR of 6.4% during the forecast period 2022 to 2030.